Page Banner
Mayo Clinic Laboratories > Neurology > Autoimmune > Neuropathies > Demyelinating neuropathies

Demyelinating neuropathies

Increase confidence through expert-backed testing

Autoimmune demyelinating neuropathies include several conditions — among them chronic inflammatory demyelinating polyneuropathy (CIDP), autoimmune nodopathy, Guillain-Barre syndrome (GBS), distal acquired demyelinating symmetric (DADS) neuropathy, chronic immune sensory polyradiculopathy (CISP), and multifocal motor neuropathy (MMN) — that share overlapping motor and/or sensory features with other peripheral neuropathies.

Used as an adjacent to nerve conduction study (NCS) and electromyography (EMG) studies, our testing can help physicians better understand the underlying etiology of a patient’s demyelinating neuropathy, which is important to accurately diagnose and treat patients.

Demyelinating neuropathies Test menu

Comprehensive Antibody Panel

Using multiple leading-edge methods, our comprehensive antibody panel detects 19 antibodies associated with autoimmune and paraneoplastic neuropathies with axonal and demyelinating causes.

This evaluation includes antibodies targeting peripheral nerves, dorsal root ganglia, and nodal and paranodal antigens, and supports diagnosis across a range of neuropathy phenotypes. These include subacute, progressive, atypical, or asymmetric presentations; autonomic involvement; and suspected immune-mediated or paraneoplastic causes.

The panel includes CASPR1 and contactin-1 (CNTN1) antibodies, including the CASPR1/CNTN1 antibody complex. Including this antibody complex supports expanded detection of antigen-specific autoimmune nodopathies by distinguishing CIDP from clinically similar conditions, since antibodies such as neurofascin-155 (NF155) and CASPR1 may be associated with CIDP mimics or other immune-mediated neuropathies.

  • CASPR1 antibodies are often associated with rapidly progressive sensorimotor neuropathy characterized by prominent neuropathic pain, distal weakness, and sensory symptoms.
  • CASPR1/contactin-1 complex antibodies are linked to prominent sensory ataxia, often with acute or subacute onset, asymmetric distribution, and occasional GBS-like features.
  • NF155 antibodies are typically associated with younger age at onset, distal weakness, pronounced sensory ataxia, and tremor.
  • CNTN1 antibodies are often linked to older age at onset, severe sensorimotor involvement, and sensory ataxia. Associated membranous nephropathy or proteinuria may provide additional supporting evidence.

In cases of antibody positivity, reflex testing is performed to confirm and further characterize the antibody, which enhances the diagnostic sensitivity of the assay.

Key testing


Demyelinating antibody evaluation

When NCS and EMG studies are suggestive of a demyelinating process, the presence of specific autoantibodies indicates that an underlying, misdirected immune response may be driving the demyelination. Our clinically validated antibody evaluation includes only those biomarkers that correlate with demyelinating neuropathies. Including wide-ranging, relevant antibodies with high clinical specificity minimizes unnecessary testing and the potential for false positive results.

Key testing

Highlights


chronic inflammatory demyelinating polyneuropathy

Frequently misdiagnosed, CIDP in most cases is highly responsive to first-line immunotherapy treatments, such as intravenous immunoglobulin (IVIG). However, a subset of individuals with specific paranodal antibodies does not respond as well to these therapies. The presence of neurofascin 155 (NF155) IgG4 and contactin-1 (CNTN1) IgG indicates a unique disease etiology, with antibodies targeting the paranode. These patients have a relatively poor treatment response to IVIG.

This assay also includes the CASPR1 autoantibody and the CASPR1/CNTN1 complex. Incorporating this complex allows for expanded detection of antigen-specific autoimmune nodopathies since individual neurofascin-155 (NF155) and CNTN1 antibodies can appear in CIDP mimics.

We’ve developed and validated a unique assay combination available exclusively at Mayo Clinic Laboratories.

Key testing

Highlights


myelin-associated glycoprotein

The presence of myelin-associated glycoprotein (MAG) antibodies is often linked to a rare demyelinating neuropathy with poor treatment response known as DADS neuropathy. In some cases, reaching a correct diagnosis through clinical and electrophysiological evaluation alone can be difficult due to overlapping features or when patient evaluation occurs later in the disease course. Incorporating MAG antibody testing into the diagnostic workup can help identify the correct diagnosis and exclude patients with treatable immune-mediated neuropathies.

Key testing

Highlights


References
  1. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013 Mar;73(3):370-80. doi:10.1002/ana.23794. Epub 2012 Dec 31. PMID: 23280477.
  2. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014 Mar 11;82(10):879-86. doi:10.1212/WNL.0000000000000205. Epub 2014 Feb 12. PMID: 24523485; PMCID: PMC3959751.
  3. Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012 Dec 4;79(23):2241-8. doi:10.1212/WNL.0b013e31827689ad. Epub 2012 Oct 24. PMID: 23100406; PMCID: PMC3542349.
  4. Dubey D, Honorat JA, Shelly S, et al. Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm. 2020 May 27;7(4):e771. doi:10.1212/NXI.0000000000000771. PMID: 32461352; PMCID: PMC7286654.
  5. Shelly S, Klein CJ, Dyck PJB, et al. Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes. Neurology. 2021 Dec 14;97(24):e2392-e2403. doi:10.1212/WNL.0000000000012932. Epub 2021 Oct 11. PMID: 34635556; PMCID: PMC8673722.
(BETA) Choose a language to view this content in:
About the translation.